Simon Shohet | Senior Director, Global Market Access and Pricing

Simon Shohet, Senior Director, Global Market Access and Pricing, Ipsen

Simon is Senior Director, Global Market and Pricing at Ipsen. He covers market access planning for pipeline and in-licensed products across Ipsen’s franchises of oncology, endocrinology and neurosciences. He also leads global market access for Ipsen’s Dysport ® brand.
Previously he has held various senior roles in international pharma consulting including IMS Consulting Group (now QuintilesIMS) and Pope Woodhead Associates where he led global assignments in pricing, managed entry scheme design, HTA policy, launch planning and value dossiers for orphan and oncology medicines. Previously, he led the medical innovation group at Sagentia Plc, specialising in commercialisation of implantables, drug delivery and diagnostics. In earlier roles Simon was policy adviser in biotechnology at the Confederation of British Industry and a Postdoctoral Fellow in Economics at London Business School. He holds a PhD in cell biology (UCL) and a Diploma in Public Affairs (CIPR).


Day Two World Pharma Pricing & Market Access EU Congress @ 09:30

Keynote Panel: Exploring effective evidence and pricing strategies

  • How can we use evidence to support market access and pricing?
  • What are the challenges and opportunities from harnessing RWE and pursuing better pricing regulation?
  • What is the viability of using pay metrics based on cost utility analyses? 

Day Two World Pharma Pricing & Market Access EU Congress @ 11:45

Evaluating the reimbursement potential of pre-launch assets – use of a “value algorithm”

back to speakers